AlphAIAlphAI — Financial news for AI agents
investing.comOCT 272 min read$KNSA

Kiniksa Pharms earnings beat by $0.19, revenue topped estimates

Kiniksa Pharma (KNSA) reported Q3 EPS of $0.56, beating estimates by $0.19, with revenue at $285.97M, exceeding expectations. Stock is down 1.83% in 3 months but up 123.48% year-over-year. InvestingPro rates its financial health as 'great performance'.

Original reporting
investing.com
Published Oct 27, 2026, 4:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 4:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$KNSA
Bullish
high confidence
Mentioned
$KNSA
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$KNSABullishMed
01

Why it matters

The surprise earnings could trigger short‑term buying pressure, but lack of forward guidance tempers the upside.

02

Market read

Earnings beat provides fresh catalyst for KNSA, potentially moving the stock in after‑hours trading.

03

What to watch

No guidance provided; future earnings remain uncertain.

Relevance 7/10Novelty 8/10Timing: post‑market today

Background

Kiniksa Pharms reported its third‑quarter results, beating analyst expectations on both earnings and revenue.

Company-level read

Ticker impact

$KNSABullishHigh confidence
Context

Q3 EPS of $0.56 beat estimates by $0.19 and revenue of $285.97M topped the $259.65M consensus.

Expected impact

likely upward pressure as investors price in the earnings beat

Evidence & confidence

The beat on both earnings and revenue is fresh information that can drive buying interest.

Market effects

Sector

Biotech sector may see modest rally as earnings beat highlights demand for pipeline.

Regional

U.S. small‑cap biotech segment could benefit from positive sentiment.

Global

Limited to U.S. investors; no broader macro impact.

Counterpoint

What could challenge this read

The beat may be priced in already; caution on short‑term volatility.

Key entities

  • company
    Kiniksa Pharms

    Biotech firm listed on NASDAQ under ticker KNSA.

Read at source← All news

StoryKiniksa Pharma posts Q3 revenue of $286 M and lifts 2026 ARCALYST sales outlook to $1.045‑$1.050 B

Also covered by

5 outlets

Related articles

OCT 27
$KNSAHigh

Kiniksa (KNSA) Q3 2026 Earnings Call Transcript

Kiniksa reported Q3 2026 revenue of $286M for ARCALYST, up 58% YoY. The company expects KPL-387 trial data in 2H 2027 and aims for a 2028-2029 launch. ARCALYST penetration in recurrent pericarditis patients reached 23%. Kiniksa forecasts $1B+ in 2026 ARCALYST revenue and is investing in AI-driven patient identification and marketing campaigns. Operating income was $54.2M, net income $47.3M, with $568.8M in cash at quarter-end.

finance.yahoo.com3 min
OCT 27
$KNSAHigh

Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals International, plc (KNSA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ ​ ​ Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution – ARCALYST ® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth – – ARCALYST 2026 expected net product revenue

SEC EDGAR 8-K3 min